Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Optimizing cystectomy outcomes.

Porten SP, Master VA.

Cancer. 2019 Jul 12. doi: 10.1002/cncr.32359. [Epub ahead of print] No abstract available.

PMID:
31299088
2.

Social Determinants of Appropriate Treatment for Muscle-Invasive Bladder Cancer.

Washington SL 3rd, Neuhaus J, Meng MV, Porten SP.

Cancer Epidemiol Biomarkers Prev. 2019 Aug;28(8):1339-1344. doi: 10.1158/1055-9965.EPI-18-1280. Epub 2019 May 15.

PMID:
31092404
3.

Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors.

Lotan Y, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Wheeler T, Lerner SP, Hutchinson R, Francis F, Davicioni E, Svatek RS, Chen CL, Black PC, Gibb EA.

Eur Urol. 2019 Aug;76(2):200-206. doi: 10.1016/j.eururo.2019.04.036. Epub 2019 May 12.

PMID:
31092337
4.

The Association Between Race and Frailty in Older Adults Presenting to a Nononcologic Urology Practice.

Washington SL 3rd, Porten SP, Quanstrom K, Jin C, Bridge M, Finlayson E, Walter LC, Suskind AM.

Urology. 2019 May;127:19-23. doi: 10.1016/j.urology.2019.02.024. Epub 2019 Feb 26.

PMID:
30822479
5.

Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer.

Balakrishnan AS, Washington SL 3rd, Meng MV, Porten SP.

Clin Genitourin Cancer. 2019 Jun;17(3):e461-e471. doi: 10.1016/j.clgc.2019.01.007. Epub 2019 Jan 19.

PMID:
30799130
6.

Epigenetic Alterations in Bladder Cancer.

Porten SP.

Curr Urol Rep. 2018 Oct 24;19(12):102. doi: 10.1007/s11934-018-0861-5. Review.

PMID:
30357502
7.

Do Women Work Less Than Men in Urology: Data From the American Urological Association Census.

Porten SP, Gaither TW, Greene KL, Baradaran N, Anger JT, Breyer BN.

Urology. 2018 Aug;118:71-75. doi: 10.1016/j.urology.2018.04.015. Epub 2018 Apr 30.

PMID:
29723591
8.

Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma.

Sanford T, Meng MV, Railkar R, Agarwal PK, Porten SP.

Clin Epigenetics. 2018 Feb 12;10:19. doi: 10.1186/s13148-018-0451-x. eCollection 2018.

9.

Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors.

Lindquist KJ, Sanford T, Friedlander TW, Paris PL, Porten SP.

PLoS One. 2017 Nov 15;12(11):e0187975. doi: 10.1371/journal.pone.0187975. eCollection 2017.

10.

The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy.

Welty CJ, Sanford TH, Wright JL, Carroll PR, Cooperberg MR, Meng MV, Porten SP.

Cancer. 2017 Dec 1;123(23):4574-4582. doi: 10.1002/cncr.30918. Epub 2017 Sep 7.

11.

Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy.

Baumann BC, Bosch WR, Bahl A, Birtle AJ, Breau RH, Challapalli A, Chang AJ, Choudhury A, Daneshmand S, El-Gayed A, Feldman A, Finkelstein SE, Guzzo TJ, Hilman S, Jani A, Malkowicz SB, Mantz CA, Master V, Mitra AV, Murthy V, Porten SP, Richaud PM, Sargos P, Efstathiou JA, Eapen LJ, Christodouleas JP.

Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):78-86. doi: 10.1016/j.ijrobp.2016.04.032. Epub 2016 May 7. Erratum in: Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1129.

12.

Intravesical chemotherapy in non-muscle-invasive bladder cancer.

Porten SP, Leapman MS, Greene KL.

Indian J Urol. 2015 Oct-Dec;31(4):297-303. doi: 10.4103/0970-1591.166446. Review.

13.

Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes.

Hussein AA, Welty CJ, Ameli N, Cowan JE, Leapman M, Porten SP, Shinohara K, Carroll PR.

J Urol. 2015 Jul;194(1):85-90. doi: 10.1016/j.juro.2015.01.077. Epub 2015 Jan 23.

PMID:
25623742
14.

Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer.

Porten SP, Willis D, Kamat AM.

Curr Opin Urol. 2014 Sep;24(5):517-23. doi: 10.1097/MOU.0000000000000089. Review.

PMID:
24921905
15.

Updated trends in imaging use in men diagnosed with prostate cancer.

Porten SP, Smith A, Odisho AY, Litwin MS, Saigal CS, Carroll PR, Cooperberg MR; Urologic Disease of America Project.

Prostate Cancer Prostatic Dis. 2014 Sep;17(3):246-51. doi: 10.1038/pcan.2014.19. Epub 2014 May 13. Review.

16.

Xanthogranulomatous pyelonephritis presenting with a left flank mass.

Zaid UB, Porten SP, Cinman NM, Sanford TH, Breyer BN.

Case Rep Med. 2013;2013:362194. doi: 10.1155/2013/362194. Epub 2013 Dec 3.

17.

Should histologic variants alter definitive treatment of bladder cancer?

Willis DL, Porten SP, Kamat AM.

Curr Opin Urol. 2013 Sep;23(5):435-43. doi: 10.1097/MOU.0b013e328363e415. Review.

PMID:
23880739
18.

Gunshot wounds to the lower urinary tract: a single-institution experience.

Cinman NM, McAninch JW, Porten SP, Myers JB, Blaschko SD, Bagga HS, Breyer BN.

J Trauma Acute Care Surg. 2013 Mar;74(3):725-30; discussion 730-1. doi: 10.1097/TA.0b013e31827e1658.

19.

The role of active surveillance in the management of prostate cancer.

Fung-Kee-Fung SD, Porten SP, Meng MV, Kuettel M.

J Natl Compr Canc Netw. 2013 Feb 1;11(2):183-7.

PMID:
23411385
20.

Active surveillance: does serial prostate biopsy increase histological inflammation?

Glass AS, Porten SP, Bonham M, Tran TC, Cowan JE, Punnen S, Chan JM, Carroll PR.

Prostate Cancer Prostatic Dis. 2013 Jun;16(2):165-9. doi: 10.1038/pcan.2012.51. Epub 2013 Jan 15.

PMID:
23318528
21.

High-risk nonmuscle invasive bladder cancer: definition and epidemiology.

Porten SP, Cooperberg MR.

Curr Opin Urol. 2012 Sep;22(5):385-9. doi: 10.1097/MOU.0b013e328356aecf. Review.

22.

Changes in cancer volume in serial biopsies of men on active surveillance for early stage prostate cancer.

Porten SP, Whitson JM, Cowan JE, Perez N, Shinohara K, Carroll PR.

J Urol. 2011 Nov;186(5):1825-9. doi: 10.1016/j.juro.2011.06.055. Epub 2011 Sep 25.

PMID:
21944082
23.

Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance.

Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR.

J Clin Oncol. 2011 Jul 10;29(20):2795-800. doi: 10.1200/JCO.2010.33.0134. Epub 2011 May 31.

24.

Factors associated with downgrading in patients with high grade prostate cancer.

Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll PR.

Urol Oncol. 2013 May;31(4):442-7. doi: 10.1016/j.urolonc.2011.02.010. Epub 2011 Apr 8.

25.

The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer.

Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR.

J Urol. 2011 May;185(5):1656-60. doi: 10.1016/j.juro.2010.12.042. Epub 2011 Mar 21.

PMID:
21419438
26.

The example of CaPSURE: lessons learned from a national disease registry.

Porten SP, Cooperberg MR, Konety BR, Carroll PR.

World J Urol. 2011 Jun;29(3):265-71. doi: 10.1007/s00345-011-0658-3. Epub 2011 Feb 24.

27.

Prostate cancer: reducing overtreatment: active surveillance in low-risk disease.

Whitson JM, Porten SP, Carroll PR.

Nat Rev Urol. 2011 Mar;8(3):124-5. doi: 10.1038/nrurol.2011.8. Epub 2011 Feb 8. No abstract available.

PMID:
21304508
28.

The outcomes of perineal urethrostomy with preservation of the dorsal urethral plate and urethral blood supply.

Myers JB, Porten SP, McAninch JW.

Urology. 2011 May;77(5):1223-7. doi: 10.1016/j.urology.2010.10.041. Epub 2011 Jan 7.

PMID:
21215434
29.

Outcomes of active surveillance for men with intermediate-risk prostate cancer.

Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR.

J Clin Oncol. 2011 Jan 10;29(2):228-34. doi: 10.1200/JCO.2010.31.4252. Epub 2010 Nov 29.

30.

Disproportionate presentation of high risk prostate cancer in a safety net health system.

Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll PR, Cooperberg MR.

J Urol. 2010 Nov;184(5):1931-6. doi: 10.1016/j.juro.2010.06.116. Epub 2010 Sep 17.

31.

Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers.

Eisner BH, Porten SP, Bechis SK, Stoller ML.

J Urol. 2010 Jun;183(6):2244-8. doi: 10.1016/j.juro.2010.02.007. Epub 2010 Apr 18.

PMID:
20400141
32.

The role of race in determining 24-hour urine composition in white and Asian/Pacific Islander stone formers.

Eisner BH, Porten SP, Bechis SK, Stoller ML.

J Urol. 2010 Apr;183(4):1407-11. doi: 10.1016/j.juro.2009.12.033. Epub 2010 Feb 20.

PMID:
20171692
33.

Hypertension is associated with increased urinary calcium excretion in patients with nephrolithiasis.

Eisner BH, Porten SP, Bechis SK, Stoller ML.

J Urol. 2010 Feb;183(2):576-9. doi: 10.1016/j.juro.2009.10.011. Epub 2009 Dec 16.

PMID:
20018328
34.

The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease.

Porten SP, Cooperberg MR, Carroll PR.

BJU Int. 2010 Feb;105(4):472-5. doi: 10.1111/j.1464-410X.2009.08774.x. Epub 2009 Aug 13.

35.

Office management of pediatric primary nocturnal enuresis: a comparison of physician advised and parent chosen alternative treatment outcomes.

Diaz Saldano D, Chaviano AH, Maizels M, Yerkes EB, Cheng EY, Losavio J, Porten SP, Sullivan C, Zebold KF, Hagerty J, Kaplan WE.

J Urol. 2007 Oct;178(4 Pt 2):1758-61; discussion 1762. Epub 2007 Aug 17.

PMID:
17707433

Supplemental Content

Loading ...
Support Center